Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials

Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-analysis of Randomized Trials

Background: Emerging data suggest that outcomes for advanced hepatocellular carcinoma (HCC) treated with sorafenib may have improved over time. We aimed to provide robust, time-to-event estimates of survival outcomes for sorafenib in advanced HCC. Summary: In this systematic review and individual...

Full description

Bibliographic Details
Main Authors:	Darren Jun Hao Tan, Ansel Shao Pin Tang, Wen Hui Lim, Cheng Han Ng, Benjamin Nah, Clarissa Fu, Jieling Xiao, Benjamin Koh, Phoebe Wen Lin Tay, Eunice X Tan, Margaret Teng, Nicholas Syn, Mark D Muthiah, Nobuharu Tamaki, Sung Won Lee, Beom Kyung Kim, Thomas Yau, Arndt Vogel, Rohit Loomba, Daniel Q. Huang
Format:	Article
Language:	English
Published:	Karger Publishers 2023-03-01
Series:	Liver Cancer
Online Access:	https://www.karger.com/Article/FullText/529824

Similar Items

Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis
by: Tan, Darren Jun Hao, et al.
Published: (2023)

A qualitative systematic review of anonymous/unspecified living kidney and liver donors' perspectives.
by: Wen Hui Lim, et al.
Published: (2022-01-01)

Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality
by: Cheng Han Ng, et al.
Published: (2022-10-01)

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
by: Tan, Darren Jun Hao, et al.
Published: (2022)

Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
by: Mark Muthiah, et al.
Published: (2023-01-01)

DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD—Analysis of 10,865 Individuals
by: Caitlyn Tan, et al.
Published: (2022-10-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals
by: Cheng Han Ng, et al.
Published: (2023-03-01)

Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC
by: Yau-Tuen Chan, et al.
Published: (2024-04-01)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
by: Shuhei Sekiguchi, et al.
Published: (2022-11-01)

The Development of Lipid-Based Sorafenib Granules to Enhance the Oral Absorption of Sorafenib
by: Jaylen C. Mans, et al.
Published: (2023-11-01)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2019-08-01)

Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
by: Benjamin Koh, et al.
Published: (2023-12-01)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021-04-01)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
by: Olivier Trédan, et al.
Published: (2023-06-01)

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
by: Jialiang Luo, et al.
Published: (2022-10-01)

Sorafenib as an Inhibitor of RUVBL2
by: Nardin Nano, et al.
Published: (2020-04-01)

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
by: Amna Mohamed Taha, et al.
Published: (2022-10-01)

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study
by: Richard S. Finn, et al.
Published: (2024-02-01)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
by: Koen G. A. M. Hussaarts, et al.
Published: (2020-08-01)

Antiglioma Potential of Coumarins Combined with Sorafenib
by: Joanna Sumorek-Wiadro, et al.
Published: (2020-11-01)

Sorafenib-Induced Capillary Leak Syndrome
by: Hyunwoo Kwon, et al.
Published: (2023-10-01)

Antitumor activity of sorafenib on colorectal cancer
by: Turgut Kacan, et al.
Published: (2016-08-01)

Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)

Sorafenib for the treatment of advanced hepatocellular carcinoma
by: M Connock, et al.
Published: (2010-05-01)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
by: Wan Wang, et al.
Published: (2019-10-01)

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism
by: Pei-Wei Shueng, et al.
Published: (2022-06-01)

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
by: Cheng Han Ng, et al.
Published: (2022-08-01)

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
by: Chun-Ming Ho, et al.
Published: (2022-01-01)

Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma
by: Zhenju Tan, et al.
Published: (2024-01-01)

Sorafenib-induced hand-foot skin reaction
by: Madhvi Trivedi, et al.
Published: (2023-01-01)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023-06-01)

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis
by: Andrea Cortese, et al.
Published: (2023-04-01)

Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
by: Sebastien Benizri, et al.
Published: (2018-01-01)

PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01)

Mental Health and Well-Being of Solid Organ Transplant Donors. The Forgotten Sacrifices
by: Xin-Hui Pan, et al.
Published: (2021-07-01)

Rates of depression, anxiety, and stress in parents of children with congenital heart disease using the Depression Anxiety Stress Scale
by: Brian K Lee, et al.
Published: (2022-01-01)

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
by: Peichun Peng, et al.
Published: (2023-04-01)

Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
by: Jina Kim, et al.
Published: (2022-05-01)

Measuring the physiological responses of Pocillopora acuta to biofilmed polyethylene microplastics exposure stress
by: Tay, Grace Syn Yee
Published: (2022)